Picture loading failed.

Pre-Made Ponezumab biosimilar, Whole mAb, Anti-APP Antibody: Anti-AAA/AD1/PN2/ABPP/CVAP/ABETA/PN-II/preA4/CTFgamma therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ponezumab is a humanized monoclonal antibody designed for the treatment of Alzheimer's disease.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-450-1mg 1mg 3090
GMP-Bios-ab-450-10mg 10mg Inquiry
GMP-Bios-ab-450-100mg 100mg Inquiry
GMP-Bios-ab-450-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Ponezumab biosimilar, Whole mAb, Anti-APP Antibody: Anti-AAA/AD1/PN2/ABPP/CVAP/ABETA/PN-II/preA4/CTFgamma therapeutic antibody
INN Name Ponezumab
TargetAPP
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI Structure3u0t:BA:DC
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2010
Year Recommended2011
CompaniesRinat Neuroscience;Pfizer
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedAlzheimer's disease;Cerebral amyloid angiopathy
Development Techna